Back to Search
Start Over
Excessive pricing in the pharmaceutical industry: adding another string to the bow of EU competition law.
- Source :
- Health Economics, Policy & Law; Jan2021, Vol. 16 Issue 1, p64-75, 12p
- Publication Year :
- 2021
-
Abstract
- The paper addresses the issue of excessive price abuse under Article 102(a) of the Treaty on the Functioning of the European Union (TFEU), by drawing inspiration from a recent stream of cases (developed first at the national and then at the EU level) involving pharmaceutical companies marketing off-patent drugs. In particular, the two 'most advanced' cases are analysed: Aspen in Italy and Pfizer/Flynn in the United Kingdom. This new-found attention towards exploitative practices in the form of excessive and unfair pricing by dominant undertakings that have traditionally been subject to a cautious antitrust scrutiny seems worth exploring for a number of reasons, as illustrated in the paper. Ultimately, it is argued that this further 'interference' of competition law into the realms of regulation may be actually justified, albeit subject to precise conditions for enforcement, and may pursue policy objectives in the wider context of EU health law. [ABSTRACT FROM AUTHOR]
- Subjects :
- DRUG laws
PHARMACEUTICAL industry
ANTITRUST law
PUBLIC health
EUROPEAN law
Subjects
Details
- Language :
- English
- ISSN :
- 17441331
- Volume :
- 16
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Health Economics, Policy & Law
- Publication Type :
- Academic Journal
- Accession number :
- 151665438
- Full Text :
- https://doi.org/10.1017/S1744133120000109